On May 17, 2022 Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), reported the appointment of Janice Lu, M.D., Ph.D., as Chief Medical Officer of Ambrx (Press release, Ambrx, MAY 17, 2022, View Source [SID1234614758]). Dr. Lu is a distinguished clinical professor of medicine who has more than 18 years of experience in leading clinical trials and breast cancer drug development.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"I am delighted to welcome Janice Lu to the Ambrx team and look forward to leveraging her insight in breast oncology to continue to progress ARX788 through the clinic," said Feng Tian, Ph.D., Chairman of the Board, President, and CEO of Ambrx. "Janice has been a valuable asset as a principal investigator for multiple Ambrx trials, including the Phase 1 ACE-Pan Tumor-01 and Phase 2 ACE-Breast-03 clinical trials, and is the ideal candidate to take the role of CMO at our company. I look forward to leaning on Janice’s expertise to further our current research and development efforts in the treatment of oncology."
"I am impressed with the encouraging data from the ongoing clinical trials of ARX788 and Ambrx’s engineered precision biologics technology platform," said Dr. Lu. "I am excited to begin working with Ambrx in this new capacity, assisting with the ongoing development of their clinical development pipeline and overseeing the clinical operations. I believe our consorted efforts will potentially provide therapeutic treatment options that are less toxic and highly targeted to patients suffering from breast, gastric, and other solid tumors."
Dr. Lu has spent her career focused on managing the treatment of women with breast cancer. Prior to her role at Ambrx, Dr. Lu was a Clinical Professor of Medicine and Medical Director of the Breast Oncology Program at the Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center. Prior to her role at USC, Dr. Lu was an Associate Professor of Clinical Medicine in the Division of Hematology and Oncology at the University of California, Los Angeles. Dr. Lu, a board certified medical oncologist, began her career at SUNY Stony Brook where she served as the Director of Breast Medical Oncology for several years.
Dr. Lu received a M.D. from Peking University School of Medicine as well as a Ph.D. from Syracuse University focusing on epigenetics under the mentorship of Dr. David Allis (Rockefeller University). Dr. Lu completed her Hematology and Oncology Fellowship at New York University School of Medicine.